Tech Company Financing Transactions
ExeVir Bio Funding Round
ExeVir Bio secured a $26.9 million investment round on 1/9/2023. Investors included European Investment Bank.
Transaction Overview
Company Name
Announced On
1/9/2023
Transaction Type
Debt
Amount
$26,900,000
Round
Undisclosed
Investors
European Investment Bank (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its lead asset, XVR012, into clinical trials for COVID-19.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Rijvisschestraat 120
Ghent, 9052
Belgium
Ghent, 9052
Belgium
Phone
Undisclosed
Website
Email Address
Overview
ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit from vaccines, such as immunocompromised individuals. The versatile VHH platform enables both prevention and treatment of bacterial and viral threats.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Torsten Mummenbrauer
Browse more venture capital transactions:
Prev: 1/9/2023: Qritive venture capital transaction
Next: 1/9/2023: Spiral Therapeutics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs